Before Wall Street escapes for summer vacation, makers of drugs and medical devices are greeting August with a frantic week of earnings reports. Here are five of the leading stocks reporting this week: • On Tuesday morning, big biotech Regeneron Pharmaceuticals (NASDAQ:REGN) is expected to report earnings of $2.77 a share, up 12% from the year-earlier quarter, according to analysts' consensus compiled by Thomson Reuters. Sales are estimated to have climbed 33% to $887.8 million. Although Regeneron has been getting a lot of attention for its new cholesterol drug Praluent lately, its Q2 results will depend on its core franchise in ophthalmology. After doing a deep dive on that field Monday, Leerink analyst Joseph Schwartz raised his price target to 630 from 559, based largely on the promise of REGN-2176, an antibody that could be a successor to Regeneron's blockbuster retinal-disease drug Eylea. He wrote that peak annual sales of that drug could hit $2 billion. Regeneron's stock, currently No. 21 on the IBD 50, was trading near 552 in midday trading Monday, down a fraction from Friday's close but remaining within 3% of its all-time high hit July 20. • Also reporting early Tuesday is specialty drugmaker Mallinckrodt (NYSE:MNK). Analysts estimate that fiscal Q3 earnings jumped 54% over last year's Q3 to $1.85 a share, with revenue up 51% to $985.3... More